NCT00675103View on ClinicalTrials.gov

Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

January 31, 2009

Study Completion Date

April 30, 2009

Conditions
Chronic Gout Refractory to Conventional Therapy
Interventions
DRUG

pegloticase 8 mg i.v.

pegloticase 8 mg i.v. every 2 weeks for 24 weeks

Trial Locations (4)

20902

The Center for Rheumatology and Bone Research, Wheaton

27710

Duke University Medical Center, Durham

60637

University of Chicago- Dept. Biological Services, Chicago

97035

Portland Rheumatology Clinic, L.L.C., Lake Oswego

Sponsors
All Listed Sponsors
lead

Savient Pharmaceuticals

INDUSTRY